Building a bridge between neurobiology and mental illness

Area of Science:

• Neuroscience
• Molecular Biology
• Psychiatry

Background:

• Gamma amino butyric acid (GABA) is the primary inhibitory neurotransmitter in the mammalian central nervous system (CNS), balancing glutamate-mediated excitation.
• Dysregulation of GABAergic function is implicated in the pathophysiology of psychoses, potentially affecting neuronal group selection and cognitive processes.
• Alterations in GABAergic systems can arise from drug administration or genetic abnormalities affecting GABA synthesis, metabolism, uptake, or GABAA receptor function.

Purpose of the Study:

• To investigate the complex regulation of GABAA receptor subunit structure, synthesis, assembly, and localization.
• To explore the role of variability in GABAA receptor allosteric modulation by endogenous and exogenous factors.
• To identify genetic abnormalities in GABAergic function as potential targets for psychiatric disorder research and therapy.

Main Methods:

• In situ mRNA hybridization was employed to study the brain localization of specific GABAA receptor subunit mRNAs.
• Analysis of genetic abnormalities in DNA transcription, pre-mRNA splicing, mRNA translation, and posttranslational modifications of GABAA receptor subunits.
• Discussion of the implications of GABAA receptor allosteric modulation variability.

Main Results:

• Complex regulatory mechanisms govern GABAA receptor subunit expression and assembly.
• Variability in GABAA receptor allosteric modulation is influenced by drug actions and endogenous modulators.
• Genetic abnormalities in proteins involved in GABAergic function are proposed as potential contributors to psychoses.

Conclusions:

• Genetic defects in GABAergic system proteins are plausible targets for understanding and treating psychiatric illnesses.
• Partial allosteric modulators (agonists) of GABAA receptors and antisense oligonucleotides targeting specific receptor subunit mRNAs show therapeutic potential.
• Future research may yield novel therapeutic strategies for genetically determined psychiatric disorders.